Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing novel biologics to restore immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases. The company's lead product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody designed to block interleukin-7 and thymic stromal lymphopoietin signaling. Bempikibart is currently in Phase 2 clinical trials for the treatment of alopecia areata and has received Fast Track designation from the U.S. Food and Drug Administration. The company previously developed a tissue-targeted complement inhibitor platform, including the asset ADX-097, which was sold to Akebia Therapeutics in late 2025. Q32 Bio retains rights to other early-stage assets from this platform, such as ADX-096, and continues to evaluate strategic options for these programs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage q32bio.com
Sector Healthcare IR page ir.q32bio.com
Tags
alopecia areata, autoimmune diseases, monoclonal antibodies, immune modulation, complement inhibitors, clinical-stage, bempikibart, ADX-914, ADX-097, ADX-096
Press page —

Metrics

Valuation  
Market cap $ 248.696M
Market cap (USD) $ 248.696M
P/E 2.40
PEG —
P/BV 0.86
P/S 4.63
P/OCF -12.42
P/FCF -7.41
Dividend yield —
Turnover / mcap —
Returns  
ROE 125.1%
ROI 57.7%
ROIC 24.5%
Profit margin 55.5%
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity 23.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score 58.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Revenue 53.737M 0
Net profit 29.821M -47.733M
Free cash flow -33.543M -67.79M

Figure FY 2025 FY 2024
Share price 3.32 3.44
Price performance 12m -0.03 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 15.4M 15.4M 23.9M 29.5M 1.32M 6.25M 5.64M
Cash and deposits (USD) 11.4M 51.6M 38.2M 53.8M 217M 108M 34M 39.3M 78M 48.3M
Right-of-use assets (USD) — — — 6.84M 5.9M 15.6M 20.6M 650,000 5.72M 5.1M
Cash flow detail
Operating cash flow (USD) — 6.48M -42.6M -91.4M -94.3M -110M -114M -96.2M -67.7M -33.5M
Purchases of property, plant and equipment (USD) — -1.96M -24.9M -21.8M -3.73M -2.4M -1.29M -228,000 -75,000 0.00
Change in payables (cash effect) (USD) — 1.72M 4.38M -4.45M 2.46M -2.49M -981,000 2.09M -1.04M -2.11M
Income taxes paid (cash effect) (USD) — — — — — 0.00 -720,000 0.00 — —
Share-based compensation (USD) — 277,000 2.62M 7.64M 13.2M 17.2M 13.1M 7.32M 4.39M 5.26M
Free cash flow (OCF - PPE - intangibles) (USD) — 4.52M -67.5M -113M -98.1M -112M -115M -96.5M -67.8M -33.5M
Income detail
Research and development expense (USD) — 21.4M 47.9M 89.4M 100M 93.1M 98.4M 62M 48.1M 19.2M
↳ 5y CAGR +35.7% +5.3% -11.6% -28.2%
Total comprehensive income (USD) — -30.1M -57.2M -104M -129M -95.8M -5.4M -113M -47.7M 29.8M
Comprehensive income to owners (USD) — -30.1M -57.2M -104M -129M -95.8M -5.4M -113M -47.7M 29.8M
Reported May 14, 2018 Mar 12, 2019 Mar 12, 2019 May 7, 2020 Mar 11, 2021 Mar 9, 2023 Mar 9, 2023 Mar 13, 2024 Mar 11, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of bempikibart as a chronic treatment in AA --

-- Robust durability, including maintenance and deepening of response, observed through the 16-week off-drug period in Part B supporting potential for less frequent, chronic maintenance dosing --

-- SIGNAL-AA Part B open-label extension (OLE) ongoing; data expected in 2H’2027 --

-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H’2027 subject to planned regulatory discussions this quarter --

-- Strengthened leadership team including appointments of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer --

-- Cash and cash equivalents of $289.6 million as of September 30, 2026 expected to provide financial runway through Phase 3 topline results from planned registration-directed program --

WALTHAM, Mass.— November 4, 2026 – Q32 Bio Inc.

September 30, 2026

PDF Version

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 --

-- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing --

-- Mechanism of action supported by biomarker results and biopsy findings --

-- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals --

-- Data supports further development of bempikibart as a chronic treatment in alopecia areata; Q32 Bio intends to advance a registration-directed program in the first half of 2027 --

WALTHAM, Mass., Sept. 30, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology ("EADV") Congress 2026. Q32 Bio previously announced topline results from this trial in July 2026. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

"We're proud to share our compelling SIGNAL-AA Part B results with the scientific community in late-breaking oral and poster presentations at EADV. We are committed to developing bempikibart as a highly differentiated, targeted treatment option for patients with alopecia areata and believe our Part B results demonstrate meaningful progress on that commitment," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "Bempikibart's robust efficacy data and durability observed across the 36-week treatment period and 16-week off-drug period in both JAK inhibitor-experienced and JAK inhibitor-naïve patients, changes on biomarkers supportive of its bifunctional mechanism, and its favorable safety and tolerability profile support its continued development in a registration-directed program in patients with severe or very severe alopecia areata as well as in expanded alopecia areata populations and other autoimmune and inflammatory indications."

"Patients and physicians currently lack a treatment option for this complex, immune driven disease that combines robust efficacy, a favorable safety profile that excludes black box warnings and other frequent monitoring requirements, and delivers durable control supporting less frequent, chronic maintenance dosing," said Arash Mostaghimi, M.D., M.P.A., M.P.H., Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School. "The SIGNAL-AA Part B results support the potential of bempikibart to address this unmet need and become a standard of care, first-line option for patients with alopecia areata, and I look forward to results from future clinical trials."

Results from Part B of the SIGNAL-AA Program:

The Part B portion of the SIGNAL-AA program is an open-label clinical trial building upon the previously completed Part A, which established proof-of-concept of bempikibart in AA. In Part B, bempikibart is being evaluated in 33 patients with severe or very severe AA (baseline Severity of Alopecia Tool ("SALT") scores of 50-100) with a maximum duration of current episode of four years. Enrollment amongst patients with prior exposure to JAK inhibitor ("JAKi") therapy was allowed; amongst the 33 enrolled patients, 36.4% had previously been treated with oral JAKis.

Total enrollment exceeded the initial target due to patient demand. In Part B, patients are treated with bempikibart for 36 weeks, with 16-week off-drug follow-up through Week 52 before optional enrollment in the open-label extension ("OLE"). Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by continued dosing of 200mg every-other-week over a 32-week period, for a total dosing period of 36 weeks. Across both regimens, bempikibart was administered subcutaneously ("SC").

The prespecified primary efficacy analysis was evaluated on the basis of mean percentage change from baseline in SALT scores in the modified intent-to-treat ("mITT") population. Additional prespecified efficacy analyses included the proportion of patients achieving various relative and absolute SALT improvements including SALT-20 (80% of scalp hair coverage), SALT30 (30% improvement in SALT score from baseline), and SALT50 (50% improvement in SALT score from baseline) responses at Week 36. Patients were then followed through the off-drug period to Week 52.

Highlights from the EADV Congress 2026 late-breaking and poster presentations include:

Results from the 36-Week Treatment Period in Part B of the SIGNAL-AA Program:

Bempikibart demonstrated clinically meaningful efficacy data on primary and key secondary endpoints at Week 36 supporting its advancement into a registration-directed program.

  • Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis.

  • 40.0% (10/25) of patients in the mITT analysis and 30.3% (10/33) of patients in the intent-to-treat ("ITT") analysis achieved a SALT-20 response.

  • In addition to SALT-20 response being observed in patients with both severe and very severe disease, it was also observed in both IgE-high and IgE-low patients and in both patients with greater than and less than two-year duration of episode.

  • 44.0% (11/25) of patients in the mITT analysis and 33.3% (11/33) of patients in the ITT analysis achieved SALT30 response.

  • 44.0% (11/25) of patients in the mITT and 33.3% (11/33) of patients in the ITT analysis achieved SALT50 response.

  • In the mITT analysis, 10 patients had received an oral JAKi before enrolling. Of these, four had responded to their most recent JAKi (defined as at least 30% improvement in SALT score) and six had not. Mean percent reduction in SALT score from baseline was 48.3% in prior JAK responders, compared with 4.8% in prior JAK non-responders. Reduction in mean SALT score of JAK-naïve patients was 44.1%.

Results from the 16-Week Off-Drug Follow-Up Period in Part B of the SIGNAL-AA Program:

Bempikibart demonstrated robust durability, with maintenance and deepening of response observed, in the 16-week off-drug follow-up period.

  • In total, 18 patients entered the 16-week off-drug period. At the 16-week off-drug time point, 44% of patients achieved a SALT-20 response, 61% achieved SALT30 response, and 50% achieved SALT50 response.

  • Of the patients who entered the off-drug follow-up period, 12 patients had demonstrated hair growth by the end of the treatment period at Week 36. Maintenance of response (with maintenance defined as a less than 20-point SALT score worsening from the last on-treatment value) was observed in 100% of these patients and deepening of response was observed in 42% of these patients. Mean SALT score in these patients remained stable through 16-weeks off-drug.

  • In the 16-week off-drug follow-up period, one patient who achieved a SALT-10 at Week 36 achieved complete hair growth (SALT = 0) and two additional patients who achieved SALT-20 at Week 36 had a deepening of response and achieved a SALT-10.

  • One latent responder during the 36-week treatment period converted to a response, achieving a SALT-20, at the end of the 16-week off-drug period.

"We are excited to show once again that bempikibart was able to induce deep, durable responses in severe and very severe alopecia areata. Responses were maintained and deepened through the 16-week off-drug period, and one latent responder converted to SALT-20 after stopping treatment, similar to what we saw in Part A, demonstrative of the potential for even greater clinical impact with continued dosing," said José Trevejo, M.D., Ph.D., Chief Medical Officer of Q32 Bio. "We believe these data support a less frequent, chronic maintenance dosing regimen once patients respond. We look forward to exploring a potential maintenance regimen in our open-label extensions as we move rapidly into registrational studies in the first half of 2027."

Pharmacokinetic ("PK"), Pharmacodynamic ("PD"), and Anti-Drug Antibody ("ADA") Profile:

Bempikibart demonstrated a favorable PK, PD and ADA profile in Part B.

  • PK data from Part B support the loading dose regimen had its intended effect, achieving steady state concentrations approximately 10 weeks earlier than in Part A.

  • Expected reductions in CD3+ T-cells were observed, with on-mechanism reductions in four T-effector cytokines assessed at baseline and Weeks 24 and 36. Patients in the upper-tier at baseline showed meaningful reductions in IFNγ, IL-17, and IL-6. CXCL10, a downstream marker of IFNγ activity, decreased meaningfully in responders versus non-responders.

  • Substantial reductions in biomarkers of Th2, including TARC, IgE and eosinophils.

  • Post-treatment biopsies showed reduced CD3+/CD8+ infiltrates around hair follicles and increased presence of anagen follicles supportive of active hair growth.

  • Negligible ADA was observed with no impact on PK.

"Reductions in Th1 and Th2 biomarkers observed across Part B further demonstrate the potential of bempikibart's unique IL-7 and TSLP inhibitory mechanism to translate into clinical benefit for patients, while biopsy results provide strong evidence of bempikibart's potential to inhibit local inflammation and restore immune homeostasis in the hair follicle," said Shelia Violette, Ph.D., Co-Founder and Chief Scientific Officer of Q32 Bio. "These results strengthen our conviction in the potential to deliver a meaningful treatment option to patients with alopecia areata and provide strong rationale for advancing bempikibart development in other autoimmune and inflammatory conditions where IL-7 and TSLP play a role."

Safety and Tolerability Results:

Bempikibart was observed to have a generally well-tolerated safety profile in SIGNAL-AA Part B, consistent with prior studies. No new safety signals were observed. There were no serious adverse events or Grade 3 or higher adverse events related to treatment. The most common treatment-emergent adverse event was injection site reaction ("ISR") (36.3%) which were primarily singular events, with ISR incidence of 4% across all Part B dose administrations. All ISRs reported were mild and resolved with no intervention, with the majority resolving within a day. On-target reduction in absolute lymphocyte count flattened at Weeks 24 to 28 with no correlation to infection events.

The presentations will be available in the "Presentations and Publications" section of the Q32 Bio website following the formal EADV presentation.

Bempikibart Development Program in AA:

Following completion of the Part B 36-week treatment period and 16-week off-drug follow-up period, eligible patients can enroll in an OLE. Enrollment and dosing remain ongoing in the OLE. Analysis from the Part B 16-week off-drug follow-up period and OLE will inform the bempikibart long-term chronic maintenance regimen, which could include monthly, bi-monthly or quarterly dosing, which will be evaluated in future studies. Q32 Bio anticipates data from the Part B OLE in the second half of 2027.

Q32 Bio plans to advance bempikibart into a registration-directed program for patients with severe or very severe AA in the first half of 2027 subject to planned regulatory discussions in the second half of 2026. Additionally, based on results observed, Q32 Bio is evaluating opportunities for bempikibart in expanded AA populations as well as in other autoimmune and inflammatory indications.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

September 21, 2026

PDF Version

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata --

WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured across late-breaking oral and poster presentations at the European Academy of Dermatology and Venereology ("EADV") Congress, taking place September 30 – October 3, 2026 in Vienna, Austria. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

"Our late-breaking oral and poster presentations highlighting additional 36-week results as well as initial findings from the 16-week off-drug period from Part B of SIGNAL-AA underscores our commitment to bringing a differentiated, targeted therapeutic to patients with alopecia areata in need of new treatment options and the growing enthusiasm for bempikibart's unique mechanism in the field," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "This recognition reinforces our conviction in our bempikibart development program in alopecia areata, as well as its potential in other autoimmune and inflammatory conditions, and we look forward to sharing our results with the scientific community."

The oral presentation details are as follows:

  • **Title:**Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial

  • **Abstract Number:**LB-375

  • **Session:**D1T01.1 – Late Breaking News

  • **Presenter:**Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School

  • **Date and Time:**Wednesday, September 30, 2026, 3:15 p.m. CEST / 9:15 a.m. EST

  • **Location:**Hall A

The poster presentation details are as follows:

  • **Title:**Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata (AA)

  • **Abstract Number:**AS-726

  • **Session:**Biologics, immunotherapy, targeted therapy

  • **Presenter:**Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School

  • **Date and Time:**Wednesday, September 30, 2026, 7:00 a.m. CEST / 1:00 a.m. EST

  • **Location:**Poster Area

The presentations will be available in the "Presentations and Publications" section of the Q32 Bio website following the formal EADV presentation.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

Prompts

Q32 Bio Inc. (ticker QTTB), listed in United States.

Company History

Date Change Detail
Mar 27, 2024 Renamed HOMOLOGY MEDICINES, INC. → Q32 BIO INC.
— Former tickers FIXX

ETFs Holding Q32 Bio Inc.

ETF Weight in ETF Shares Market value As of
AVUV 0.01% 528,167 $ 4.379M Nov 16, 2026
AVSC 0.01% 34,455 $ 285.632K Nov 16, 2026
DXUV 0.00% 9,437 $ 83.234K Nov 12, 2026
DFAS 0.00% 40,897 $ 360.712K Nov 12, 2026
DFAT 0.00% 33,287 $ 293.591K Nov 12, 2026
DFAC 0.00% 3,035 $ 26.769K Nov 12, 2026
AVUS 0.00% 17,858 $ 148.043K Nov 16, 2026
AVSU 0.00% 1,049 $ 8,696.21 Nov 16, 2026